Press Release: ReNetx : Remedy Pharmaceuticals Co-founder and CEO Brings Clinical Trial and Company-Building Experience to ReNetX Bio Advisory Board

Sven Jacobson will be the first to admit that developing a new therapeutic for spinal cord injury is a challenging road. But the latest member of the ReNetX Advisory Board sees the promise of their first-in-class therapeutic in development to treat chronic spinal cord injury, and has the experience to help guide the clinical studies needed to move that drug forward.